Eluvia drug-eluting Vascular Stent System for the Treatment of Symptomatic Femoropopliteal Lesions

References

• Fowkes FG , RudanD, RudanIet al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis . Lancet382 ( 9901 ), 1329 – 1340 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ , BlahaMJ, ChiuveSEet al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association . Circulation135 ( 10 ), e146 – e603 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Kalbaugh CA , Kucharska-NewtonA, WruckLet al. Peripheral artery disease prevalence and incidence estimated from both outpatient and inpatient settings among medicare fee-for-service beneficiaries in the Atherosclerosis Risk in Communities (ARIC) study . J. Am. Heart Assoc.6 ( 5 ), pii:e003796 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Hirsch AT , HaskalZJ, HertzerNRet al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation . Circulation113 ( 11 ), e463 – e654 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Nehler MR , DuvalS, DiaoLet al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population . J. Vasc. Surg.60 ( 3 ), 686e682 – 695e682 ( 2014 ).
   Web of Science ®Google Scholar
• Sigvant B , LundinF, WahlbergE . The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease . Eur. J. Vasc. Endovasc. Surg.51 ( 3 ), 395 – 403 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Rooke TW , HirschAT, MisraSet al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . J. Am. Coll. Cardiol.61 ( 14 ), 1555 – 1570 ( 2013 ).
   PubMedGoogle Scholar
• Aboyans V , RiccoJB, BartelinkMELet al. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) . Eur. Heart J.39 ( 9 ), 763 – 816 ( 2017 ).
   Google Scholar
• Costa MA , SimonDI . Molecular basis of restenosis and drug-eluting stents . Circulation111 ( 17 ), 2257 – 2273 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Iida O , UematsuM, SogaYet al. Timing of the restenosis following nitinol stenting in the superficial femoral artery and the factors associated with early and late restenoses . Catheter. Cardiovasc. Interv.78 ( 4 ), 611 – 617 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Tepe G , LairdJ, SchneiderPet al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and/or popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial . Circulation131 ( 5 ), 495 – 502 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bausback Y , Willfort-EhringerA, SievertHet al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon . J. Endovasc. Ther.24 ( 4 ), 459 – 467 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Rosenfield K , JaffMR, WhiteCJet al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease . N. Engl. J. Med.373 ( 2 ), 145 – 153 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Krishnan P , FariesP, NiaziKet al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: 12-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies . Circulation136 ( 12 ), 1102 – 1113 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Kastrati A , DibraA, SpauldingCet al. Meta-analysis of randomized trials on drug-eluting stents vs bare-metal stents in patients with acute myocardial infarction . Eur. Heart J.28 ( 22 ), 2706 – 2713 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Dake MD , AnselGM, JaffMRet al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results . Circ. Cardiovasc. Interv.4 ( 5 ), 495 – 504 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• O’Gara PT , KushnerFG, AscheimDDet al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines . J. Am. Coll. Cardiol.61 ( 4 ), e78 – e140 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ibanez B , JamesS, AgewallSet al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC) . Eur. Heart J.39 ( 2 ), 119 – 177 ( 2017 ).
   Web of Science ®Google Scholar
• Valgimigli M , BuenoH, ByrneRAet al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) . Eur. Heart J.39 ( 3 ), 213 – 260 ( 2017 ).
   Web of Science ®Google Scholar
• Müller-Hülsbeck S , KeirseK, ZellerT, SchroeH, Diaz-CartelleJ . Twelve month results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for treatment of obstructive femoropopliteal disease . J. Endovasc. Ther.23 ( 5 ), 701 – 707 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Duda SH , BosiersM, LammerJet al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial . J. Endovasc. Ther.13 ( 6 ), 701 – 710 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Lammer J , BosiersM, ZellerTet al. First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease . J. Vasc. Surg.54 ( 2 ), 394 – 401 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schroeder H , MeyerDR, LuxB, RueckerF, MartoranaM, DudaS . Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study . Catheter. Cardiovasc. Interv.86 ( 2 ), 278 – 286 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Dake MD , AnselGM, JaffMRet al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies . J. Am. Coll. Cardiol.61 ( 24 ), 2417 – 2427 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Dake MD , AnselGM, JaffMRet al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial . Circulation133 ( 15 ), 1472 – 1483 ; discussion 1483 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Müller-Hülsbeck S . Eluvia peripheral stent system for the treatment of peripheral lesions above the knee . Expert Opin. Drug Deliv.13 ( 11 ), 1639 – 1644 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hou D , HuibregtseBA, EppihimerMet al. Fluorocopolymer-coated nitinol self-expanding paclitaxel-eluting stent: pharmacokinetics and vascular biology responses in a porcine iliofemoral model . EuroIntervention12 ( 6 ), 790 – 797 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Stone GW , TeirsteinPS, MeredithITet al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a prospective, randomized, multicenter trial to assess an everolimus-eluting coronary stent system [PROMUS element] for the treatment of up to two de novo coronary artery lesions) trial . J. Am. Coll. Cardiol.57 ( 16 ), 1700 – 1708 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wilson GJ , HuibregtseBA, StejskalEAet al. Vascular response to a third generation everolimus-eluting stent . EuroIntervention6 ( 4 ), 512 – 519 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Powell RJ , JaffMR, SchroeH, BenkoA, Diaz-CartelleJ, Muller-HulsbeckS . Stent placement in the superficial femoral and proximal popliteal arteries with the innova self-expanding bare metal stent system . Catheter. Cardiovasc. Interv.89 ( 6 ), 1069 – 1077 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Gasior P , ChengY, ValenciaAFet al. Impact of fluoropolymer-based paclitaxel delivery on neointimal proliferation and vascular healing: a comparative peripheral drug-eluting stent study in the familial hypercholesterolemic swine model of femoral restenosis . Circ. Cardiovasc. Interv.10 ( 5 ), e004450 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Müller-Hülsbeck S , KeirseK, ZellerT, SchroeH, Diaz-CartelleJ . Long-term results from the MAJESTIC trial of the Eluvia paclitaxel-eluting stent for femoropopliteal treatment: 3-year follow-up . Cardiovasc. Interv. Ther.40 ( 12 ), 1832 – 1838 ( 2017 ).
   Google Scholar
• Scheinert D , ScheinertS, SaxJet al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting . J. Am. Coll. Cardiol.45 ( 2 ), 312 – 315 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Katsanos K , GeislerBP, GarnerAM, ZayedH, ClevelandT, PietzschJB . Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK . BMJ Open6 ( 5 ), e011245 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Health Quality Ontario . Paclitaxel drug-eluting stents in peripheral arterial disease: a health technology assessment . Ont. Health Technol. Assess. Ser.15 ( 20 ), 1 – 62 ( 2015 ).
   Google Scholar
• Pietzsch JB , GeislerBP, GarnerAM, ZellerT, JaffMR . Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany . Catheter. Cardiovasc. Interv.84 ( 4 ), 546 – 554 ( 2014 ).
   PubMed Web of Science ®Google Scholar